Dr Linton is a Clinical Senior Lecturer in the Division of Molecular & Clinical Cancer Sciences at The University of Manchester, honorary Consultant in Medical Oncology at The Christie NHS Foundation Trust, and Chair of the Christie Lymphoma Group. She has a specialist interest in the clinical management of lymphoma focussed on early phase clinical drug development and advanced cellular therapies. Since her consultant appointment in 2009, she has been local principal investigator on over 50 industry sponsored and investigator led clinical trials, with an extensive trials portfolio from first in man to late phase clinical drug development.  She is currently UK co-chief investigator for REFRACT, an NCRI investigator led clinical trial, and lead UK investigator for the NCRI PETReA international trial as well as co-investigator on the international NCRI RADAR trial. She leads several industry-sponsored international clinical trials as UK chief investigator and/or site principal investigator, and serves on the trial management group for four UK NCRI trials. She is also leading real world observational studies in follicular and mantle cell lymphoma and has authored over 60 peer-reviewed publications, including lymphoma guidelines, patient information booklets and textbook chapters.

Dr Linton has a PhD in Molecular Pathology from The University of Manchester and runs a programme of translational research at the Manchester Cancer Research Centre, focussed on lymphoma biomarker development and late effects of lymphoma treatment. Current and future projects include development of lung cancer screening programmes in Hodgkin Lymphoma survivors, biomarkers for anthracycline-induced cardiovascular toxicity and novel prognostic biomarkers in Follicular and Hodgkin Lymphoma.  She chairs the second cancers theme for the BRC Living With and Beyond Cancer Sciences Centre, which received renewed NIHR funding in 2022. 

She holds external national and international leadership positions, including chair of the UK NCRI Low Grade Lymphoma Study Group and membership of the NCRI Lymphoma Research Group and several of its study groups and working parties. She is the Scientific Secretary of the European Haematology Association Lymphoma Scientific Working Party, and a steering committee member for Women in Lymphoma, a global organisation advocating for greater female research leadership. She is also a medical advisor for Lymphoma Action and co-led a work package within the Innovate Manchester Advanced Therapy Centre Hub to develop the infrastructure for safe delivery of advanced cellular medicinal products across Manchester.  She provides external consultancy for the Pharma Industry and National Institute for Health and Care Excellence (NICE) and serves on steering committees for Genmab and Roche pharmaceutical companies.

Dr Linton is a clinical and educational supervisor for speciality and academic foundation trainees in medical oncology and examiner and supervisor for doctoral and masters dissertations. She serves on the MRes Oncology Programme committee and co-leads the Clinical Masterclass Module. She lectures on several University of Manchester and external accredited courses, including the Lymphoma Action Lymphoma Management Course.

Dr Linton was awarded a medical degree from the University of Cape Town in 1994. She joined The Christie as a Specialist Registrar in 2000 and obtained a PhD in molecular pathology from the University of Manchester in  2007. She was appointed to her current role in 2009 as Clinical Senior Lecturer and Honorary Consultant in Medical Oncology at The University of Manchester and Christie NHS Fondation Trust, respectively. The was elected as a fellow of the Royal College of Physicians in 2020.

• Circulating and imaging biomarkers of chemotherapy induced cardiotoxicity in lymphoma - a collaborative project with The Stoller Biomarker Centre and The Manchester Heart Centre to investigate biomarkers of drug-induced cardiac damage in anthracycline treated animal and clinical models. 
• Lung cancer screening in Hodgkin Lymphoma survivors – a BRC-2 Living With and Beyond Cancer (LWBC) project funded by The Roy Castle Lung Cancer Foundation, Christie Charity, NIHR GM PSTRC and Manchester BRC 
• Development of a commercialization strategy for hypothesized interaction distribution as a patient stratification biomarker in follicular lymphoma. A Wellcome A2E funded project.  
• Relapsed Follicular lymphoma Randomised trial Against standard ChemoTherapy (REFRACT): A randomised phase II trial of investigator choice standard salvage immuno-chemotherapy versus sequential novel therapy experimental arms. A CR-UK funded investigator led randomised clinical trial.
• PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma (PETReA). A CR-UK funded investigator led international randomised clinical trial.
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma. A takeda-funded international clinical trial.
• Investigation of integrated biological and PET imaging biomarkers (bioPET) for the risk-adapted management of early stage Hodgkin Lymphoma; a Blood Cancer UK funded sub-study of the RAPID clinical trial.
• Investigation of CSF microRNAs as potential diagnostic and prognostic markers in Primary Central Nervous System Lymphoma. Funded by Lymphoma Research Trust.
• FOUNDATION UK: A retrospective observational study of outcomes for contemporary therapy in relapsed Follicular Lymphoma. Roche funded UK study. 
• Investigation of genetic and epigenetic biomarkers of chemotherapy response in patients treated for peripheral T cell lymphoma; an ongoing collaborative Christie, Royal Marsden and Royal Liverpool University Hospital project
• Investigation of FLT3 ligand as a biomarker of neutropenic complications in patients treated for lymphoma; a Pfizer-funded translational substudy of the NCRN-endorsed phase ll INCA trial

Research Students 2021-2022:

PhD: Anna Maria Tsakiroglou AM (awarded 2021), Rachel Broadbent (completes 2022), Rohan Shotton (completes 2024)

MRes: Anne Tivey (-2020); James Whiteway (-2020); Ranjeet Singh (-2021)

APEP: Ekram Omer (-2020) Rory Williams (-2021)

Clinical Supervisor: Kok Haw Jonathan Lim (2020) Prerana Huddar (2021); Laura Woodhouse (2021), Daniel Netto (2022)

Educational Supervisor: Mohammed Adam Ibrahim Dawod (2021); Tiana Kordbacheh (2021); Rachel Broadbent (2021)

Physician Academic Supervisor: Anne Tivey (2021); Rachel Broadbent (2021), Rohan Shotton (2021)

Local: John Radford, Tim Illidge, Richard Unwin,  Chris Miller, Martin Fergie, Beth Phillips, Chris Armitage,  Gareth Evans, Phil Crosbie, Tania Seale, Joanna Oladipo, Richard Byers, Anna Maria Tsakiroglou, Janet Taylor Caroline Dive, Dominic Rothwell, Marianne Aznar, Claire Higham, Rohan Shotton, Rachel Broadbent, Annie Tivey

National: Mark Bishton, Andrew McMillan, David Baldwin (Nottingham), Graham McIlroy, Sonia Fox, Aimee Jackson, Louise Hopkins (Birmingham), Jessica Okosun, Alan Ramsay, Sally Barrington, Nick Counsell, David Cunningham, Mary Gleeson, Amy Kirkwood,  (London), Ingo Ringshausen (Cambridge), Andrew Pettitt (Liverpool), Cathy Burton (Leeds), Graham Collins, Toby Eyre, David Cutter (Oxford), David Lewis (Plymouth)

International: Judith Trotman, Maher Gandhi (Australia), Marie-Jose Kersten,  Sanne Tonino (Netherlands), Michael Crump, Lois Shepherd (Canada), Stefan Chauvie, Arjun Diepstra, Wouter Plattel (EU), Christian Steidl (USA)

• Chair, NCRI Low Grade Lymphoma Study Group
• Chair, Christie Lymphoma Group
• Scientific Secretary, EHA Lymphoma Scientific Working Group
• Member, National Cancer Research Institute (NCRI) Lymphoma Research Group, high grade lymphoma subgroups and the T cell and Primary CNS Lymphoma working parties.
• Member, British Society for Haematology Specialist Interests Group (term completed 2020).
• Member, Lymphoma Action Medical Advisory Panel
• Medical expert adviser, National Institute for Health and Care Excellence (NICE) Centre for Clinical Guidelines (term completed 2020)
• Steering Committee Member, Women In Lymphoma 
• Member, Epcoritamab Global Council
• Member, Roche Haematology Steering Group
• Member, BSH Special Interests Group (completed 2020)
• Programme Committee Member and co-lead for clinical masterclass module, MRes Oncology Course
• Writing group member, British Committee for Standards in Haematology Guideline Committees
• Fellow, Royal College of Physicians
• Member, Association of Cancer Physicians
• Member, Medical Protection Society

Microarray gene expression profiling of FFPE, biomarker discovery/development, phase l-lll lymphoma clinical trials

MBChB (University of Cape Town, 1994)

MRCP (Edinburgh, 1999)

PhD (The University of Manchester, 2007)

FRCP (London, 2020)